Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 746 participants.
Also called NCT02100514
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 746 participants
- Sponsor
- Registry
-
NCT02100514 -
2014-000478-20
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Finland, Netherlands, Norway, Poland, Puerto Rico, Singapore, South Korea, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02100514. Randomized; triple masking; primary purpose treatment. Start 2014-10-28 (actual); primary completion 2016-07-15 (actual). Results posted on 2017-07-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
- Acronym
- SPIRE-LL
- Condition
- Hyperlipidemia
- Intervention (Drug)
- Bococizumab (PF-04950615; RN316)
- Intervention (Other)
- Placebo
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct02100514- Content hash
29794032b6fcbc25edece739cb7152992021baba9ac5ba8e25c516b745acf957